Alex Philippidis

BrainChild Bio raises $116M Series A to launch pivotal registrational trial of BCB-276 CAR T therapy for pediatric DIPG

BrainChild Bio, a Seattle Children’s spinout, raised $116 million in Series A funding to support a pivotal registrational trial of BCB-276, an autologous CAR T-cell therapy targeting DIPG in children, with plans to expand into adult CNS tumors including glioblastoma.